GSK, Vir Begin Phase 2/3 Trial of COVID-19 Antibody Treatment

GlaxoSmithKline and Vir Biotechnology have dosed the first patient in a phase 2/3 clinical trial of their investigational COVID-19 antibody treatment VIR-7831 for early treatment in patients at high risk of hospitalization.

The study will assess whether a single dose of VIR-7831 can prevent the hospitalization of COVID-19 patients. The drugmakers aim to enroll 1,300 participants with mild to moderate COVID-19 who are at high risk for severe progression.

Initial results of the trial could be available by the end of 2020, and complete results are expected in the first quarter of 2021.